Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and ...

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Supernus (SUPN) with an Overweight rating and $57 price target Supernus has ...

Now, the New York Times bestselling author of This Will Only Hurt a Little is teaming up with Supernus Pharmaceuticals to raise awareness about ADHD and Qelbree, a once-daily, non-stimulant ...

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...

For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the ...

NASDAQ SUPN opened at $35.59 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The company has a 50 day moving average of $35.65 and a 200-day ...

Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals ... A live webcast with presentation sl Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine ...